Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Umoja Biopharma

AbbVie engages in pharmaceutical research and development to provide innovative solutions for patients.

AbbVie

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Alaunos Therapeutics, Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Metric
Company Name	Umoja Biopharma	AbbVie	Alaunos Therapeutics, Inc.	ALX Oncology Holdings Inc.
Symbol			TCRT	ALXO
MSH ID	COM:UMOJA-BIOPHARMA	AR:COM:ABBVIE	COM:ALAUNOS	COM:ALXONCOLOGY
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Biotechnology
Country	US	AR	US	US
Stage
Employee Count			1	74
Website	umoja-biopharma.com	abbvie.com.ar	alaunos.com	alxoncology.com
LinkedIn
Founders

Metric
Market Cap		9.61M	352.20M
Enterprise Value
Monthly Web Traffic	6.83K
Web Traffic Growth	-0.19
Valuation
Raised Capital

Metric
Revenue			5K
Revenue (LTM)
Revenue (NTM)
Gross Profit			-4.80M
EBITDA			-34.27M
Operating Income			-34.27M
Net Income			-35.14M
EPS			-0.00
Diluted EPS			-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-217
Operating Profit Margin			-2.32K
EBITDA Margin			-6.85K
Net Profit Margin			-2.43K
Return on Equity			-1.41
Return on Assets			-1.87
Return on Capital Employed			-2.36

COM:UMOJA-BIOPHARMA

Umoja Biopharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-14.38
P/B Ratio			37.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			4.36K
EV Multiple			-0.43

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding			0.00
Operating Cycle			243.33
Cash Conversion Cycle			141.48
Asset Turnover			0.00

Metric
Operating Cash Flow			-30.14M
Free Cash Flow			-30.34M
Cash Flow to Debt
Operating Cash Flow/Sales			-1.99K
Free Cash Flow Yield			-0.86

Metric
Cash & Equivalents			6.06M
Accounts Receivable			3K
Inventory
Goodwill
Debt to Capitalization			0.08
Debt to Assets			0.06
Current Ratio			2.75
Quick Ratio			5.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			228.47
R&D to Revenue			1.40K
SG&A to Revenue			1.30K